Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net income	$ 7,149	$ 3,127
Adjustments to reconcile to net cash provided by (used in) operating activities:
Depreciation and amortization	9,783	7,502
(Gain) loss on sale of fixed assets	13	(17)
Equity-based compensation expense	1,541	1,827
Deferred income taxes	836	(1,159)
Equity in earnings of affiliated companies	(652)	(853)
(Gain) loss on foreign currency transactions	(843)	13
Other	1,172	(330)
Changes in operating assets and liabilities:
Restricted cash	(677)	521
Return on equity method investments		3,110
Receivables net, retainage and costs and estimated earnings in excess of billings	11,371	5,183
Inventories	126	(881)
Prepaid expenses and other assets	2,353	1,292
Accounts payable and accrued expenses	(13,308)	(22,741)
Other operating	319	(1,195)
Net cash provided by (used in) operating activities	19,183	(4,601)
Cash flows from investing activities:
Capital expenditures	(11,447)	(3,692)
Proceeds from sale of fixed assets	2,714	141
Patent expenditures	(219)	(286)
Receipt of cash from Hockway sellers due to final net working capital adjustments	1,048
Purchase of Fyfe Latin America, net of cash acquired	(3,048)
Purchase of Fyfe North America	(532)
Net cash used in investing activities	(11,484)	(3,837)
Cash flows from financing activities:
Proceeds from issuance of common stock, including tax effects	671	2,639
Investments from noncontrolling interests	3,920	141
Distributions/dividends to noncontrolling interests		(776)
Repurchase of common stock	(6,037)
Principal payments on notes payable	(633)
Proceeds from line of credit	26,000
Proceeds from long-term debt	983
Principal payments on long-term debt	(6,250)	(2,500)
Other financing activities		(87)
Net cash provided by (used in) financing activities	18,654	(583)
Effect of exchange rate changes on cash	(2,032)	1,535
Net increase (decrease) in cash and cash equivalents for the period	24,321	(7,486)
Cash and cash equivalents, beginning of period	106,129	114,829
Cash and cash equivalents, end of period	$ 130,450	$ 107,343